PHAR

Pharming Group NV ADR

12.60

Nov 13 • 3:59 PM ET -0.35 (-2.70%)

12.60

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology Netherlands Small NASD

Peers: PHVS BCRX NTLA IONS ADMA TAK RARE MIRM ARGX KNSA

Scroll to Statements

Index	-
Market Cap	891.83M
Enterprise Value	816.78M
Income	24.04M
Sales	386.69M
Book/sh	4.11
Cash/sh	2.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	-
IPO	Dec 23, 2020

P/E	40.00
Forward P/E	34.59
PEG	0.23
P/S	2.31
P/B	3.06
P/C	4.70
P/FCF	31.84
EV/EBITDA	17.63
EV/Sales	2.11
Quick Ratio	2.65
Current Ratio	3.23
Debt/Eq	0.39
LT Debt/Eq	0.36
Option/Short	No / Yes

EPS (ttm)	0.32
EPS next Y	0.36
EPS next Q	0.10
EPS this Y	781.00%
EPS next Y	3.37%
EPS next 5Y	148.88%
EPS past 3/5Y	-41.84% -41.23%
Sales past 3/5Y	22.40% 12.25%
EPS Y/Y TTM	2242.07%
Sales Y/Y TTM	6.67%
EPS Q/Q	174.95%
Sales Q/Q	21.29%
Earnings	Oct 27 BMO
EPS/Sales Surpr.	42.86% 0.00%

Insider Own	-
Insider Trans	-
Inst Own	0.12%
Inst Trans	21.77%
ROA	4.95%
ROE	8.65%
ROIC	6.06%
Gross Margin	82.77%
Oper. Margin	8.84%
Profit Margin	6.22%
SMA20	5.52%
SMA50	14.98%
SMA200	-6.30%
Trades

Shs Outstand	70.78M
Shs Float	-
Short Float	-
Short Ratio	1.15
Short Interest	0.03M
52W High	21.34 -40.96%
52W Low	9.11 38.31%
Volatility	4.02% 3.83%
ATR (14)	0.54
RSI (14)	59.60
Beta	-0.08
Rel Volume	0.23
Avg Volume	22.39K
Volume	5,078

Perf Week	2.52%
Perf Month	30.84%
Perf Quarter	6.87%
Perf Half Y	-2.48%
Perf YTD	-28.69%
Perf Year	-28.49%
Perf 3Y	15.60%
Perf 5Y	39.23%
Perf 10Y	-
Recom	1.00
Target Price	30.64
Prev Close	12.95
Price	12.60
Change %	-2.70%

Consensus

Strong Buy

Avg. Price Target

$30.64

Implied Upside

+143.2%

Analysts2incl. previous ratings

Rating Distribution2 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 10, 2026	Initiated	CCanaccord Genuity	Buy	$37	+193.7%
Dec 09, 2024	Initiated	JJefferies	Buy	$14	+11.1%

Nov-11-26 02:00AM	Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-06-26 01:00AM	MHRA approves Pharming's Joenja (leniolisib) as first treatment specifically for children with APDS in the U.K. (GlobeNewswire)
Oct-27-26 02:00AM	Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November (GlobeNewswire)
Oct-22-26 01:00AM	Pharming Group announces third quarter 2026 revenues above market expectations (GlobeNewswire) +10.57%
Oct-14-26 02:00AM	Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026 (GlobeNewswire)
01:00AM	Loading…
Sep-29-26 01:00AM	Pharming announces CEO transition (GlobeNewswire)
Sep-25-26 10:30AM	Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja to treat children with APDS (GlobeNewswire)
Jul-30-26 03:04PM	Pharming Group (PHGUF) (Q2 2026) Earnings Call Highlights: Joenja Surges 40% as Ruconest Faces ... (GuruFocus.com) -10.49%
Jul-29-26 10:00AM	Earnings To Watch: Pharming Group (XAMS:PHARM) Q2 2026 -- GF Value Sees 36% Upside (GuruFocus.com) -6.61%
May-06-26 09:27AM	Pharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-12-26 03:05PM	Pharming Group (PHGUF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Mar-11-26 09:24AM	Pharming Group (XAMS:PHARM) Q4 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Mar-03-26 08:07AM	Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? (Zacks)
Mar-01-26 08:18AM	Pharming Group Touts 2025 Sales Surge, Joenja Expansion Plans at Oppenheimer Healthcare Conference (MarketBeat)
Feb-04-26 04:18AM	Pharming Group Investor Day: 2026 revenue outlook tops Street as Joenja growth, readouts loom (MarketBeat)
04:24PM	Loading…
Feb-02-26 04:24PM	Why Pharming, A Top 3% Biotech Stock, Just Took A Double-Digit Beating (Investor's Business Daily) -17.07%
09:04AM	FDA Strikes Off European Biotech Pharming's Immune Deficiency Drug For Expanded Use In Pediatric Patients (Benzinga)
Dec-22-25 10:15AM	Best Momentum Stocks to Buy for Dec. 22 (Zacks) +6.56%
Nov-26-25 09:55AM	Wall Street Analysts Believe Pharming Group (PHAR) Could Rally 81.71%: Here's is How to Trade (Zacks)
Nov-20-25 09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out? (Zacks)
Nov-10-25 12:20PM	Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy? (Zacks) +13.74%
09:55AM	Does Pharming Group (PHAR) Have the Potential to Rally 100.91% as Wall Street Analysts Expect? (Zacks)
Nov-05-25 07:43AM	What To Expect From Pharming Group (XAMS:PHARM) Q3 2025 Earnings (GuruFocus.com)
Sep-26-25 10:05AM	CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program (Zacks) -6.82%
Sep-25-25 11:07AM	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study (Zacks)
Sep-22-25 11:29AM	FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing (Zacks)
Sep-15-25 09:52AM	Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain (Zacks) -5.38%
Sep-12-25 11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks) +9.55%
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
11:06AM	Loading…
Sep-04-25 11:06AM	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results (Zacks)
Sep-03-25 09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
Sep-02-25 09:03AM	Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus (Zacks) -5.94%
Aug-29-25 10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks)
Aug-26-25 11:16AM	Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin (Zacks) -6.16%
Aug-22-25 09:55AM	Wall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High? (Zacks) +8.21%
Aug-06-25 09:55AM	Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet (Zacks)
Aug-04-25 02:00AM	Pharming Group to participate in August investor conference (GlobeNewswire) +11.77%
Aug-01-25 05:25AM	New Strong Buy Stocks for August 1st (Zacks)
Jul-31-25 01:00AM	Pharming Group reports second quarter and first half 2025 financial results and provides business update (GlobeNewswire) +10.11%
Jul-25-25 10:00AM	Best Momentum Stocks to Buy for July 25th (Zacks)
07:12AM	New Strong Buy Stocks for July 25th (Zacks)
Jul-17-25 10:00AM	Best Momentum Stocks to Buy for July 17th (Zacks)
05:38AM	New Strong Buy Stocks for July 17th (Zacks)
02:00AM	Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31 (GlobeNewswire)
Jun-24-25 01:00AM	Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis (GlobeNewswire) +8.58%
Jun-11-25 11:15AM	Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders (GlobeNewswire)
May-28-25 02:00AM	Pharming Group to participate in June investor conferences (GlobeNewswire) -7.22%
May-08-25 01:00AM	Pharming Group reports first quarter 2025 financial results and provides business update (GlobeNewswire) +11.22%
Apr-30-25 11:45AM	Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director (GlobeNewswire)
Apr-25-25 09:00AM	Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) (GlobeNewswire)
08:09AM	SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-24-25 10:55AM	Pharming announces positive recommendation from NICE for Joenja (TipRanks)
02:00AM	Pharming Group to report first quarter 2025 financial results on May 8 (GlobeNewswire)
Apr-23-25 03:30AM	Pharming receives positive recommendation from NICE for Joenja (leniolisib) as a treatment for APDS (GlobeNewswire)
Apr-03-25 01:00AM	Pharming Group announces the filing of its 2024 Annual Report and Form 20-F (GlobeNewswire) -8.11%
Apr-01-25 08:45AM	Pharming Group: Small Dutch Company With Strong Revenues (Seeking Alpha)
Mar-28-25 03:00AM	Pharming Group to participate in April investor conferences (GlobeNewswire)
Mar-20-25 02:00AM	Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation (GlobeNewswire)
Mar-13-25 02:00AM	Pharming Group reports fourth quarter and full year 2024 financial results and provides business update (GlobeNewswire) +12.92%
Mar-04-25 09:15AM	Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders (GlobeNewswire)
Feb-28-25 02:00AM	Pharming Group to participate in March investor conference (GlobeNewswire)
Feb-27-25 02:00AM	Pharming Group to report fourth quarter and full year 2024 financial results on March 13 (GlobeNewswire) -6.62%
Feb-20-25 04:00PM	Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent (GlobeNewswire) +5.05%
Feb-10-25 02:00AM	Pharming Group to participate in February investor conference (GlobeNewswire)
Feb-07-25 04:00PM	Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period (GlobeNewswire)
Jan-21-25 12:00PM	Pharming Group to convene Extraordinary General Meeting of Shareholders (GlobeNewswire)
01:00AM	Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer (GlobeNewswire)
Dec-15-24 01:45PM	Pharming announces public cash offer to the shareholders of Abliva AB (GlobeNewswire)
Dec-11-24 01:00AM	Pharming announces positive topline data in pediatric clinical trial of leniolisib (GlobeNewswire) +6.07%
Nov-05-24 02:00AM	Pharming Group to participate in November investor conference (GlobeNewswire)
Oct-24-24 01:00AM	Pharming Group reports third quarter 2024 financial results and provides business update (GlobeNewswire) -7.37%
Oct-10-24 02:00AM	Pharming Group to report third quarter 2024 financial results on October 24 (GlobeNewswire)
01:00AM	Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation (GlobeNewswire)
Sep-26-24 01:00AM	Pharming announces marketing authorization in the U.K. for Joenja (leniolisib) (GlobeNewswire)
Sep-04-24 01:00AM	Pharming Group to participate in September investor conferences (GlobeNewswire)
Aug-01-24 01:00AM	Pharming Group reports second quarter and first half 2024 financial results and provides business update (GlobeNewswire) -8.40%
Jul-18-24 02:00AM	Pharming Group to report second quarter and first half 2024 financial results on August 1 (GlobeNewswire)
Jun-03-24 02:00AM	Pharming Group to participate in June investor conferences (GlobeNewswire)
May-30-24 04:44PM	Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union (GlobeNewswire)
May-21-24 11:30AM	Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
May-20-24 02:00AM	Pharming Group to participate in May investor conference (GlobeNewswire)
May-15-24 01:00AM	Pharming Group announces the early redemption of the remaining outstanding 125 million convertible bonds due 2025 (GlobeNewswire)
May-08-24 06:52AM	PHAR Stock Earnings: Pharming Reported Results for Q1 2024 (InvestorPlace)
06:16AM	Pharming Group uproots angioedema gene therapy collab with Orchard (FierceBiotech.com)
01:00AM	Pharming Group reports first quarter 2024 financial results and provides business update (GlobeNewswire)
May-02-24 06:00AM	Genomenon Partners with Pharming to Advance APDS Diagnosis (PR Newswire)
Apr-24-24 02:00AM	Pharming Group to report first quarter 2024 financial results on May 8 (GlobeNewswire)
01:00AM	Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD ) 2024 Rare Impact Awards (GlobeNewswire)
Apr-22-24 05:29AM	Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains? (Zacks)
Apr-19-24 12:43PM	Pharming Group announces the repurchase of outstanding 125 million convertible bonds due 2025 (GlobeNewswire) +7.18%
Apr-18-24 09:04AM	Pharming Group announces the placement of 100 million convertible bonds due 2029 (GlobeNewswire) -8.26%
02:00AM	Pharming Group announces the launch of an offering of approximately 100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding 125 million convertible bonds due 2025 (GlobeNewswire)
Apr-08-24 01:00AM	Pharming announces completion of enrollment in pediatric clinical trial of leniolisib (GlobeNewswire)
Apr-04-24 02:30AM	Pharming Group announces the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
01:00AM	Pharming Group announces the filing of its 2023 Annual Report and Form 20-F (GlobeNewswire)
Apr-03-24 02:00AM	Pharming Group to participate in April investor conferences (GlobeNewswire)
Mar-14-24 02:00AM	Pharming Group reports fourth quarter and full year 2023 financial results (GlobeNewswire)
Feb-29-24 02:00AM	Pharming Group to report fourth quarter and full year 2023 financial results on March 14 (GlobeNewswire)
Feb-08-24 02:00AM	Pharming Group to participate in February investor conferences (GlobeNewswire) -7.19%

Show Previous News

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST, Joenja, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

M.Sc.Mr. Kenneth Lynard EMBA

Co-CEO & Chief Commercial OfficerMs. Leverne Marsh BPHARM

Chief Operations OfficerMs. Mireille Sanders M.Sc.

VP of Investor Relations & Corporate CommunicationsMr. Michael K. Levitan

Chief Legal & Compliance Officer and Company SecretaryMr. Ruud Van Outersterp L.L.M.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

PHAR

Pharming Group NV ADR

Upgrade your Finviz experience

All the Features.
Half the Price.